白雲山(600332.SH):何濟公藥廠《藥品生產許可證》新增生產地址、生產車間和生產線
格隆匯11月9日丨白雲山(600332.SH)公佈,近日,廣州白雲山醫藥集團股份有限公司分公司廣州白雲山醫藥集團股份有限公司白雲山何濟公制藥廠(簡稱“何濟公藥廠”)收到廣東省藥品監督管理局核准簽發的《藥品生產許可證》,同意何濟公藥廠《藥品生產許可證》新增生產地址“普寧市英歌山工業區英歌山大道北側”、生產車間“普寧製造部”、生產線“橡膠膏劑(溶劑法)生產線”。
經對普寧製造部橡膠膏劑(溶劑法)生產線進行藥品生產質量管理規範符合性檢查,此次檢查範圍“橡膠膏劑”符合《藥品生產質量管理規範(2010年修訂)》要求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.